• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VSee Health Provides a Business Update and Reports Second Quarter 2024 Financial Results

    9/23/24 1:00:00 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care
    Get the next $VSEE alert in real time by email

    VSee Health, Inc. (NASDAQ:VSEE), a provider of comprehensive telehealth services that customize workflow streams and enhance patient care, today provided a business update and reported financial results for the three and six months ended June 30, 2024.

    Business Highlights

    • Successfully completed the de-SPAC transaction and now publicly traded as VSee Health, following the merger between VSee Lab and iDoc Telehealth into Digital Health Acquisition Corp., thereby enhancing our service capabilities, particularly in acute care and tele-intensivist services.
    • Partnered with Ava Robotics for the development of a VSee Health-powered Ava robot that allows providers to extend their reach and provide personalized care remotely to hospital intensive care units.
    • Launched Aimee, an innovative virtual healthcare, labs and prescription drug service that patients can access whether or not they have health insurance, providing low-cost access to quality healthcare.
    • Contracted with Seven Corners Correctional Health, the operator of 24 federal prisons, to offer accessible, quality specialty care to the inmate population they serve.
    • Expanded our telehealth and billing services to major healthcare clients through a partnership with SkywardRx, including nonprofit, hospital and Fortune 20 corporate clients.
    • Secured a virtual care purchasing agreement with Premier, Inc., expanding our reach and penetration in key healthcare markets.

    Management Commentary

    "The accomplishments by VSee Health during the second quarter and subsequent weeks underscore our commitment to enhance the healthcare experience through innovative virtual care business-to-business solutions, and our financial results reflect the transition of Digital Health Acquisition Corp. from a SPAC to an operating company," said Imo Aisiku, M.D., co-CEO and Chairman of VSee Health. "Becoming publicly traded marks a significant milestone not only for access to the public equity markets, but also in finalizing the merger between VSee Lab and iDoc Virtual Telehealth Solutions, leveraging our strengths to enable expanded partnerships and service offerings. This transaction was a critical launching pad to accelerate our growth, trigger more investment in improving technology solutions and scale customer acquisition to new heights."

    "We believe that through developing robust telemedicine solutions that easily integrate into existing healthcare systems, VSee Health is increasingly becoming recognized as a trusted brand and critical component of a provider's toolkit. As example, our telehealth offering has been a success in the Federal Bureau of Prisons with 24 of the 122 facilities onboard.. By securing partnerships such as with the Koch brothers-founded Stand Together in launching Aimee, we are helping to develop local community centers into healthcare hubs that have the capability of providing high quality physician access at affordable levels.. Broadening our range of services allowed us to enter new markets, which is crucial as we scale operations. In addition, we believe these strategic moves should enable us to set the stage for additional revenue opportunities in 2025 and beyond as we continue to innovate and strive to capture market share in the rapidly evolving telehealth industry," added Milton Chen, Ph.D., co-CEO of VSee Health.

    Second Quarter Financial Results

    Second quarter consolidated financial statements include the accounts of VSee Health, Inc. and its subsidiaries, VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc., which are both 100% wholly-owned subsidiaries of VSee Health following the business combination on June 24, 2024.

    Revenue was $1.7 million for the second quarter of 2024, compared to $1.3 million for the second quarter of 2023, an increase of 33%. Higher professional and other fees and technical and engineering fees primarily drove the revenue increase. Professional and other fees increased by 93% due to higher hardware purchases from new customers, and technical and engineering fees increased by 290% due to a higher volume of engineering, customizations and integration services provided to existing and new customers. Subscription revenue also increased slightly and the acquisition of iDoc led to higher fees.

    Operating expenses for the second quarter of 2024 increased 69% compared with the prior-year quarter. The increase was driven by higher transaction expenses related to the business combination, led by higher legal, professional, advisory and consulting fees. The increase was also driven by higher general and administrative expenses due to higher reseller fees, slightly offset by lower software cost from the lower headcounts, resulting in lower utilization of software licenses. These increases were offset by lower compensation and related benefits, primarily from lower utilization of independent contractors and employee headcount reduction.

    Net loss for the second quarter of 2024 was $0.3 million, or $0.06 per share, compared a net loss for the second quarter of 2023 of $0.4 million, or $0.09 per share. The 16% decrease was driven by the tax benefit primarily related to valuation allowance changes related to the business combination and by higher revenue, and were slightly offset by higher operating expenses primarily due to the business combination.

    Six Month Financial Results

    Revenue was $3.2 million for the first half of 2024, compared with $2.9 million for the first half of 2023, an increase of 11%. Higher professional and other fees and technical and engineering fees primarily drove the revenue increase. Professional and other fees increased by 57% due to higher hardware purchases from new customers during the current quarter, and technical and engineering fees increased by 57% due to a higher volume of engineering, customizations and integration services provided to existing and new customers. The increase was also driven by higher fees, primarily from patient and telehealth fees, from the acquisition of iDoc. These increases were offset by a 6% decline in subscription revenue due to the churned enterprise customers in 2024 with little to no clinic usage, as some clients gradually shifted back to face-to-face consultations.

    Operating expenses for the first half of 2024 increased 13% over the comparable period last year. The increase was driven by higher transaction expenses related to the business combination, led by higher legal, professional, advisory and consulting fees. The increase was also driven by higher general and administrative expenses due to the iDoc acquisition and higher reseller fees, slightly offset by lower software and business service costs from lower headcounts, resulting in lower utilization of software licenses. These increases were offset by lower compensation and related benefits, primarily from lower utilization of independent contractors and employee headcount reduction.

    Net loss for the first half of 2024 was $0.3 million, or $0.07 per share, compared with a net loss for the first half of 2023 of $0.9 million, or $0.19 per share. The 62% decrease was driven by the income tax benefit primarily related to the valuation allowance changes related to the business combination and higher revenue, slightly offset by higher operating expenses, primarily due to the business combination.

    As of June 30, 2024, VSee Health had cash and cash equivalents of $1.1 million.

    Pro Forma Financial Results

    The unaudited pro forma financial information in the tables below summarizes the combined results of VSee Health's operations and iDoc's operations, as though the acquisition of iDoc had been completed as of the beginning of 2023.

    Total revenues for the second quarter of 2024 were $2.7 million compared with $2.8 million for the second quarter of 2023. Total revenues for the first half of 2024 were $5.8 million compared with $6.3 million for the first half of 2023.

    The net loss for the second quarter of 2024 was $1.8 million, or $0.12 per share, compared with a net loss of $1.0 million, or $0.07 per share, for the second quarter of 2023. The net loss for the first half of 2024 was $2.0 million, or $0.14 per share, compared with a net loss of $2.1 million, or $0.14 per share, for the first half of 2023.

    The following table summarizes the pro forma financial information:

     

     

    For the Three Months Ended June 30,

     

    For the Six Months Ended June 30,

     

     

    2024

     

    2023

     

    2024

     

    2023

    Total revenue

     

    $

    2,701,485

     

     

    $

    2,769,241

     

     

    $

    5,837,245

     

     

    $

    6,314,200

     

    Net loss

     

    $

    (1,791,264

    )

     

    $

    (1,030,910

    )

     

    $

    (2,002,771

    )

     

    $

    (2,106,741

    )

    Weighted average shares:

     

     

     

     

     

     

     

     

     

     

     

     

    Basic and diluted

     

     

    14,694,087

     

     

     

    14,692,820

     

     

     

    14,693,450

     

     

     

    14,692,820

     

    Net Loss per share:

     

     

     

     

     

     

     

     

     

     

     

     

    Basic and diluted

     

    $

    (0.12

    )

     

    $

    (0.07

    )

     

    $

    (0.14

    )

     

    $

    (0.14

    )

    About VSee Health

    VSee Health is a software-as-a-service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. VSee Health's system allows a telehealth mobile app to be created or a telehealth system to be integrated into existing hospital operations in days.

    With a focus on patient disease state telemedicine and turnkey billing services, VSee Health has integrated an intensive care, critical care and neuro solution, powered by iDoc Telehealth Solutions, as its initial module for the VSee Health software platform. This technology encompasses a set of integrated telehealth technologies and a team of neurointensivists, neurologists, and tele-radiologists that who treat and coordinate care for acutely ill patients 24/7/365 in the neuro-intensive care unit (Neuro-ICU), cardiac surgery intensive care unit (CS-ICU) and the intensive care unit (ICU) for stroke, brain trauma and a wide range of neurological conditions. For more information, please visit www.vseehealth.com.

    Forward-Looking Statements

    Matters discussed in this news release that are not statements of historical or current facts, including but not limited to those relating to VSee Health's ability to improve healthcare access and provider efficiencies, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause performance or achievements to be materially different from historical results or from any future performance or achievements expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. More information on risk factors relating to VSee Health and its technology and billing services is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of VSee Health's periodic and current filings with the SEC, which are also made available on VSee Health's website at www.vseehealth.com. Forward-looking statements speak only as of the date they are made, and VSee Health undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, or otherwise.

    (Tables follow)

    CONDENSED CONSOLIDATED BALANCE SHEETS

     

     

     

     

     

     

     

     

     

    June 30,

     

    December 31,

     

     

    2024

     

    2023

     

     

    (Unaudited)

     

     

     

    ASSETS

     

     

     

     

     

     

    Current assets

     

     

     

     

     

     

    Cash

     

    $

    1,105,971

     

     

    $

    118,734

     

    Accounts receivable, net of allowance for credit losses of $1,741,238 and $32,457 as of June 30, 2024, and December 31, 2023, respectively

     

     

    2,513,855

     

     

     

    628,480

     

    Due from related party

     

     

    785,934

     

     

     

    —

     

    Prepaids and other current assets

     

     

    760,789

     

     

     

    79,920

     

    Total current assets

     

     

    5,166,549

     

     

     

    827,134

     

     

     

     

     

     

     

     

    Note receivable, related party

     

     

    245,500

     

     

     

    —

     

    Right-of-use assets, net (related party portion $260,373 and zero as of June 30, 2024, and December 31, 2023, respectively)

     

     

    691,684

     

     

     

    —

     

    Intangible assets

     

     

    12,100,000

     

     

     

    —

     

    Goodwill

     

     

    59,900,694

     

     

     

    —

     

    Fixed assets, net

     

     

    883,323

     

     

     

    3,657

     

    Total assets

     

    $

    78,987,750

     

     

    $

    830,791

     

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

     

     

     

     

     

     

    Current liabilities

     

     

     

     

     

     

    Accounts payable and accrued liabilities

     

    $

    6,752,985

     

     

    $

    1,824,408

     

    Deferred revenue

     

     

    1,023,492

     

     

     

    802,524

     

    Due to related party

     

     

    456,858

     

     

     

    338,506

     

    Right-of use liability - operating (related party portion $101,401 and zero as of June 30, 2024, and December 31, 2023, respectively)

     

     

    222,910

     

     

     

    —

     

    Right-of use liability - financing

     

     

    507,538

     

     

     

    —

     

    Factoring payable

     

     

    348,463

     

     

     

    —

     

    Encompass Purchase liability

     

     

    268,038

     

     

     

    —

     

    SAFE Note

     

     

    —

     

     

     

    135,000

     

    Contingent liability

     

     

    —

     

     

     

    600,000

     

    ELOC

     

     

    638,321

     

     

     

    —

     

    ELOC Note

     

     

    500,000

     

     

     

    —

     

    Additional Bridge Note

     

     

    397,408

     

     

     

    —

     

    Exchange Note

     

     

    5,666,873

     

     

     

    —

     

    Quantum Convertible Note

     

     

    4,697,050

     

     

     

    —

     

    Loan payable, related party, net of discount

     

     

    471,651

     

     

     

    323,000

     

    Line of credit and note payable, net of discount

     

     

    928,280

     

     

     

    220,000

     

    Total current liabilities

     

     

    22,879,867

     

     

     

    4,243,438

     

     

     

     

     

     

     

     

    Line of credit and notes payable, less current portion, net of discount

     

     

    593,941

     

     

     

    —

     

    Right-of-use liability - operating, less current portion (related party portion $163,658 and zero as of June 30, 2024, and December 31, 2023, respectively)

     

     

    471,507

     

     

     

     

    Right-of-use liability - financing, less current portion

     

     

    231,879

     

     

     

    —

     

    Total liabilities

     

     

    24,177,194

     

     

     

    4,243,438

     

     

     

     

     

     

     

     

    Commitments and contingencies (Note 9)

     

     

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity (deficit)

     

     

     

     

     

     

    Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 6,158 and zero shares issued and outstanding as of June 30, 2024, and December 31, 2023, respectively

     

     

    1

     

     

     

    —

     

    Common stock, $0.0001 par value; 100,000,000 shares authorized 14,806,820 and 4,639,643 shares issued and outstanding as of June 30, 2024, and December 31, 2023, respectively

     

     

    1,481

     

     

     

    464

     

    Additional paid-in capital

     

     

    64,582,130

     

     

     

    6,027,153

     

    Accumulated deficit

     

     

    (9,773,056

    )

     

     

    (9,114,985

    )

    Non-controlling interest

     

     

    —

     

     

     

    (325,279

    )

    Total stockholders' equity (deficit)

     

     

    54,810,556

     

     

     

    (3,412,647

    )

    Total liabilities and stockholders' equity (deficit)

     

    $

    78,987,750

     

     

    $

    830,791

     

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS



    FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024, AND 2023 (UNAUDITED)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    For the Three Months Ended June 30,

     

    For the Six Months Ended June 30,

     

     

    2024

     

    2023

     

    2024

     

    2023

    Revenues

     

     

     

     

     

     

     

     

     

     

     

     

    Subscription fees

     

    $

    1,037,426

     

     

    $

    1,022,631

     

     

    $

    2,042,628

     

     

    $

    2,183,822

     

    Professional services and other fees

     

     

    421,632

     

     

     

    218,942

     

     

     

    749,475

     

     

     

    478,332

     

    Technical engineering fees

     

     

    189,939

     

     

     

    48,650

     

     

     

    352,889

     

     

     

    224,337

     

    Patient fees

     

     

    31,520

     

     

     

    —

     

     

     

    31,520

     

     

     

    —

     

    Telehealth fees

     

     

    30,569

     

     

     

    —

     

     

     

    30,569

     

     

     

    —

     

    Institutional fees

     

     

    480

     

     

     

    —

     

     

     

    480

     

     

     

    —

     

    Total Revenue

     

     

    1,711,566

     

     

     

    1,290,223

     

     

     

    3,207,561

     

     

     

    2,886,491

     

    Cost of goods sold

     

     

    486,640

     

     

     

    474,287

     

     

     

    872,893

     

     

     

    1,049,609

     

    Gross margin

     

     

    1,224,926

     

     

     

    815,936

     

     

     

    2,334,668

     

     

     

    1,836,882

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

     

     

    Compensation and related benefits

     

     

    918,411

     

     

     

    1,084,618

     

     

     

    1,811,988

     

     

     

    2,420,170

     

    General and administrative

     

     

    509,050

     

     

     

    326,386

     

     

     

    660,398

     

     

     

    607,639

     

    Transaction expenses

     

     

    980,807

     

     

     

    16,059

     

     

     

    1,007,145

     

     

     

    57,345

     

    Total operating expenses

     

     

    2,408,268

     

     

     

    1,427,063

     

     

     

    3,479,531

     

     

     

    3,085,154

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net operating loss

     

     

    (1,183,342

    )

     

     

    (611,127

    )

     

     

    (1,144,863

    )

     

     

    (1,248,272

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Other income (expenses):

     

     

     

     

     

     

     

     

     

     

     

     

    Interest expense

     

     

    (349,695

    )

     

     

    (79,860

    )

     

     

    (359,005

    )

     

     

    (127,262

    )

    Other income

     

     

    2

     

     

     

    3

     

     

     

    2

     

     

     

    19,619

     

    Change in fair value of financial instruments

     

     

    548,100

     

     

     

    88,008

     

     

     

    548,100

     

     

     

    114,077

     

    Loss on issuance of financial instruments

     

     

    (1,618,234

    )

     

     

    —

     

     

     

    (1,618,234

    )

     

     

    —

     

    Total other (expenses) income

     

     

    (1,419,827

    )

     

     

    8,151

     

     

     

    (1,429,137

    )

     

     

    6,434

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Loss before income taxes

     

     

    (2,603,169

    )

     

     

    (602,976

    )

     

     

    (2,574,000

    )

     

     

    (1,241,838

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Benefit from income tax

     

     

    2,241,208

     

     

     

    174,395

     

     

     

    2,241,208

     

     

     

    357,238

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net loss

     

     

    (361,961

    )

     

     

    (428,581

    )

     

     

    (332,792

    )

     

     

    (884,600

    )

    Net loss attributable to non-controlling interest

     

    $

    (31,980

    )

     

    $

    (3,971

    )

     

    $

    —

     

     

    $

    (8,738

    )

    Net loss attributable to stockholders

     

    $

    (329,981

    )

     

    $

    (424,610

    )

     

    $

    (332,792

    )

     

    $

    (875,862

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic and diluted loss per common share

     

    $

    (0.06

    )

     

    $

    (0.09

    )

     

    $

    (0.07

    )

     

    $

    (0.19

    )

    Weighted average number of common shares outstanding, basic and diluted

     

     

    5,302,490

     

     

     

    4,639,643

     

     

     

    4,971,066

     

     

     

    4,639,643

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240923555945/en/

    Get the next $VSEE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSEE

    DatePrice TargetRatingAnalyst
    2/24/2025$5.00Buy
    Maxim Group
    More analyst ratings

    $VSEE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VSee New AI Doctor Notes Reduces Documentation Time 93% – Transforming Virtual Emergency Care for Tele911

    VSee Health, Inc. (NASDAQ:VSEE) a leading provider of secure digital health solutions, today announced the launch of its new AI doctor notes, one of the solutions in its AI solutions suite. VSee has partnered with Tele911, the largest national telemedicine emergency room diversion service, to integrate VSee's AI Doctor Notes into its virtual emergency care workflow. Emergency medicine demands rapid decision-making and high patient throughput. The integration has drastically reduced Tele911 physician's charting time by 93% from 15 minutes per visit to under 1 minute, potentially increasing physician visit capacity. This new VSee AI solution automatically transcribes visits and generates

    7/14/25 8:17:00 AM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial

    VSee Health, Inc. (NASDAQ:VSEE) a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation based out of UCLA—the second such national trial of post-stroke telerehabilitation. The trial spans 29 hospitals and 202 patients, and will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke survivors while reducing costs like transportation, caregiver burdens, and hospital readmissions. The proven efficacy of Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke re

    6/23/25 8:27:00 AM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    VSee Health, Inc. Receives Nasdaq Notice on Delayed Form 10-Q Filing

    VSee Health, Inc. (the "Company") (NASDAQ:VSEE), announced today that on May 23, 2025, the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025, and its Annual Report on Form 10-K for the period ended December 31, 2024, the Company is not in compliance with Nasdaq's listing rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Nasdaq notice has no immediate effect on the listing or trading of the Company's common stock or its public warrants on The Nasdaq Capital Market.

    5/30/25 4:07:00 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    $VSEE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on VSee Lab with a new price target

    Maxim Group initiated coverage of VSee Lab with a rating of Buy and set a new price target of $5.00

    2/24/25 8:42:03 AM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    $VSEE
    SEC Filings

    View All

    SEC Form 424B3 filed by VSee Health Inc.

    424B3 - VSEE HEALTH, INC. (0001864531) (Filer)

    3/5/26 6:01:08 AM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    VSee Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - VSEE HEALTH, INC. (0001864531) (Filer)

    3/3/26 4:05:42 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    VSee Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - VSEE HEALTH, INC. (0001864531) (Filer)

    2/19/26 5:15:22 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    $VSEE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director O'Sullivan Colin P. was granted 40,107 shares, increasing direct ownership by 58% to 108,731 units (SEC Form 4)

    4 - VSEE HEALTH, INC. (0001864531) (Issuer)

    3/6/26 4:31:01 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    Director Metzger Scott was granted 40,107 shares, increasing direct ownership by 52% to 117,356 units (SEC Form 4)

    4 - VSEE HEALTH, INC. (0001864531) (Issuer)

    3/6/26 4:30:33 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    Director Lowdermilk Kevin was granted 40,107 shares, increasing direct ownership by 58% to 108,731 units (SEC Form 4)

    4 - VSEE HEALTH, INC. (0001864531) (Issuer)

    3/5/26 4:32:42 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    $VSEE
    Financials

    Live finance-specific insights

    View All

    VSee Health Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / December 20, 2024 / RedChip Companies will air an interview with VSee Health, Inc. (NASDAQ:VSEE) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, December 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interview in its entirety at: https://www.redchip.com/assets/access/vsee_accessIn an exclusive interview, Milton Chen, PhD, co-CEO of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated solutions position the company as a growing leader in the $787 billion telehealth

    12/20/24 9:00:00 AM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so

    12/2/24 4:05:00 PM ET
    $SXTP
    $VSEE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    $VSEE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by VSee Health Inc.

    SC 13G/A - VSEE HEALTH, INC. (0001864531) (Subject)

    11/14/24 8:45:14 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by VSee Health Inc.

    SC 13G/A - VSEE HEALTH, INC. (0001864531) (Subject)

    11/14/24 5:23:34 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by VSee Health Inc.

    SC 13G - VSEE HEALTH, INC. (0001864531) (Subject)

    7/5/24 4:29:01 PM ET
    $VSEE
    Medical/Nursing Services
    Health Care